Zobrazeno 1 - 10
of 277
pro vyhledávání: '"Ignacio Duran"'
Autor:
Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O’Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of
Externí odkaz:
https://doaj.org/article/1fe44534f0e94c6a89809b887b29866b
Autor:
Enrique Perez-Navarro, Vincenza Conteduca, Juan M. Funes, Jose I. Dominguez, Miguel Martin-Serrano, Paolo Cremaschi, Maria Piedad Fernandez-Perez, Teresa Alonso Gordoa, Albert Font, Sergio Vázquez-Estévez, Aránzazu González-del-Alba, Daniel Wetterskog, Begona Mellado, Ovidio Fernandez-Calvo, María José Méndez-Vidal, Miguel Angel Climent, Ignacio Duran, Enrique Gallardo, Angel Rodriguez Sanchez, Carmen Santander, Maria Isabel Sáez, Javier Puente, Julian Tudela, Cecilia Marinas, María Jose López-Andreo, Daniel Castellano, Gerhardt Attard, Enrique Grande, Antonio Rosino, Juan A. Botia, Jose Palma-Mendez, Ugo De Giorgi, Enrique Gonzalez-Billalabeitia
Publikováno v:
Cancers, Vol 16, Iss 14, p 2535 (2024)
The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution of distinct whole
Externí odkaz:
https://doaj.org/article/1b834549def9418a9fbae464adb1f954
Autor:
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot
Publikováno v:
European Urology Open Science, Vol 50, Iss , Pp 1-9 (2023)
Background: Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy. Objective: To bett
Externí odkaz:
https://doaj.org/article/859488fb49644ff6bbf4afa1b1012ee4
Autor:
Ignacio Duran
Publikováno v:
Ensayos de Política Económica, Vol 3, Iss 3, Pp 77-105 (2021)
El presente trabajo analiza el comportamiento cíclico de la inscripción en educación superior de adultos jóvenes. Para esto se desarrolla un modelo de datos de panel para los países de la Unión Europea entre el año 2000 y el 2018. En primer lu
Externí odkaz:
https://doaj.org/article/92e7e85c902f48698b3e391298d4d256
Autor:
Nataliya Mar, Yousef Zakharia, Alejandro Falcon, Rafael Morales-Barrera, Begona Mellado, Ignacio Duran, Do-Youn Oh, Stephen K. Williamson, Pablo Gajate, Hendrik-Tobias Arkenau, Robert J. Jones, Min Yuen Teo, Tolga Turan, Robert T. McLaughlin, Hillary M. Peltier, Elizabeth Chong, Harisha Atluri, James P. Dean, Daniel Castellano
Publikováno v:
Cancers, Vol 15, Iss 11, p 2978 (2023)
Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. We evaluated the safety and efficacy of ibrutinib, alone or combined with standard-of-
Externí odkaz:
https://doaj.org/article/3f71cdaeba5f4c0e924f34247590ed6e
Autor:
Sidra Khalid, Bassam Mohammed Basulaiman, Jeffrey Emack, Christopher M. Booth, Ignacio Duran, Andrew G. Robinson, David Berman, Martin Smoragiewicz, Eitan Amir, Francisco E. Vera-Badillo
Publikováno v:
European Urology Open Science, Vol 21, Iss , Pp 61-68 (2020)
Background: Fibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials. Objective: We aimed to study the association between FGFR3 mutations and survi
Externí odkaz:
https://doaj.org/article/97a165ed87b24c6d964a86fb6984384a
Autor:
Brian W. Labadie, Ping Liu, Riyue Bao, Michael Crist, Ricardo Fernandes, Laura Ferreira, Scott Graupner, Andrew S. Poklepovic, Ignacio Duran, Saman Maleki Vareki, Arjun V. Balar, Jason J. Luke
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-12 (2019)
Abstract Background Clinical variables may correlate with lack of response to treatment (primary resistance) or clinical benefit in patients with clear cell renal cell carcinoma (ccRCC) treated with anti-programmed death 1/ligand one antibodies. Meth
Externí odkaz:
https://doaj.org/article/11c6c7749828478981cee977f6da34c0
Autor:
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within
Externí odkaz:
https://doaj.org/article/26c0983875fa4d0da5e0fc2f0a11a2aa
Autor:
Hector Terán-Navarro, Andrea Zeoli, David Salines-Cuevas, Marco Marradi, Noemi Montoya, Elena Gonzalez-Lopez, Javier Gonzalo Ocejo-Vinyals, Mario Dominguez-Esteban, Jose Luis Gutierrez-Baños, Felix Campos-Juanatey, Sonsoles Yañez-Diaz, Almudena Garcia-Castaño, Fernando Rivera, Ignacio Duran, Carmen Alvarez-Dominguez
Publikováno v:
Cancers, Vol 14, Iss 10, p 2413 (2022)
This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 nanovaccines showed ad
Externí odkaz:
https://doaj.org/article/e2fc9b314064462eb5eb9ed5a719946d
Autor:
Marta Espinosa, Juan Maria Roldán-Romero, Ignacio Duran, Enrique de Álava, María Apellaniz-Ruiz, Alberto Cascón, Carmen Garrigos, Mercedes Robledo, Cristina Rodriguez-Antona
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-5 (2018)
Abstract Background Renal epithelioid angiomyolipomas (EAML) are rare tumors with aggressive behavior. EAML can be sporadic or develop within the tuberous sclerosis complex syndrome, where mutations of TSC1 or TSC2 genes (critical negative regulators
Externí odkaz:
https://doaj.org/article/2bd539ec21a8436dba069747c6d59b14